Boys Tennis clinches section championship over Schaeffer Academy! Headed to state!

Section Champs!

globenewswire.com/news-release/2…

Treos Bio Announces Presentation of Final Results from Phase 1b Study of PolyPEPI1018 Immunotherapy for Late-Stage Metastatic Colorectal Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting globenewswire.com/news-release/2…

This group is one of my lifelines❤️ thank you Mass General Cancer Center MGH Women in Oncology

Boys Tennis defeats Rock Ridge 4-3 to advance to the state finals!

Congratulations Marjan!!

🎓Test Yourself & learn! Top experts Gerald Prager & Joleen Hubbard (Joleen Hubbard) lead this interactive patient case study. Learn; > How to achieve a long-term response > What 3rd-line treatments are available 👉ow.ly/YxSl50PSpJf Endorsed by Digestive Cancers Europe #MedEd

Congrats Yelena Y. Janjigian MD, the coauthors and patients on KN-811 The Lancet just out! #ESMO23 #cancer re: the role of #immunotherapy + HER-2 therapy in metastatic #UGI cancers. #cancerresearch #clinicaltrials Memorial Sloan Kettering Cancer Center

Presenting out latest research showing the PolyPEPI1018 peptide vaccine combined with immunotherapy induced immune responses both serologically and in the tumor microenvironment in MSS CRC oncologypro.esmo.org/meeting-resour…

Overall pathological response rate of 100% for dMMR CRC! dailyreporter.esmo.org/esmo-congress-…

Amazingly new data out today from Sweden 🇸🇪 showing an incredible decline in prevalence of the HPV virus as a result of the vaccine HPV causes cancer .. This is going to save a lot of lives Vaccines are incredible !

We need to bring biomarker testing in GI cancer up to the same standard we apply in breast cancer (where patients themselves are savvy enough to know & self-sort by receptor status) Excellent summary of contemporary testing of gastric cancer #gi25

ctDNA in CRC is prognostic, but there is no data showing that treatment initiated earlier based upon ctDNA positivity confers improved survival (or QOL). Earlier detection alone does not equal benefit. Great job Kristen Ciombor 👏👏 #GI25

Front row seats to BREAKWATER data—improved ORR and DOR with enco/cetux plus FOLFOX when compared to SOC in 1L BRAF mut mCRC. #GI25

👏 Checkmate 8HW: Nivo +/- ipi in metastatic dMMR (MSI-H) w/superior PFS vs. nivo alone (39.3M vs. NR, HR = 0.62, p-value = 0.0003) creating a NEW standard of care; RR = 71% vs. 58% (p = 0.0011). Med f/U~4yrs. #colorectal #cancer @asco #ASCOGI25 OncoAlert Bristol Myers Squibb FDA Oncology

Much awaited nivo/ipi vs nivo data from CheckMate 8HW in 1L MSI-H mCRC - nivo/ipi better in PFS and ORR across all lines of therapy with expected increase in toxicity #GI25 Concomitant publication in the Lancet today for more details!

New standards of care from ASCO GI 2025! 1) FOLFOX + encorafenib + cetuximab for 1st line BRAF mutant mCRC, 2) ipilumumab + nivolumab for 1st line MSI-H mCRC

Wells Messersmith giving a masterful discussion on (in my opinion) the most impactful data of #GI25